Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn

被引:19
作者
Bae, Soo Kyung [2 ]
Gwak, Jungsug [1 ]
Song, Im-Sook [3 ]
Park, Hyung-Soon [4 ]
Oh, Sangtaek [1 ]
机构
[1] Kookmin Univ, Dept Adv Fermentat Fus Sci & Technol, Seoul 136702, South Korea
[2] Catholic Univ Korea, Coll Pharm, Puchon 420743, South Korea
[3] Inje Univ, Coll Med, PharmcoGenom Res Ctr, Pusan 614735, South Korea
[4] Probiond Co Ltd, Seoul 143834, South Korea
关键词
Topoisomerase I inhibitor; p53; Colon cancer; Apoptosis; RESISTANCE PROTEIN; MULTIDRUG-RESISTANCE; COLORECTAL-CANCER; DNA TOPOISOMERASES; TUMOR-SUPPRESSOR; P53; TOPOTECAN; DRUGS; TRIAL; CAMPTOTHECINS;
D O I
10.1016/j.bbrc.2011.04.108
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The tumor suppressor p53 plays an important role in cellular emergency mechanisms through regulating the genes involved in cell cycle arrest and apoptosis. To identify small molecules that can activate p53-responsive transcription, we performed chemical screening using genetically engineered HCT116 reporter cells. We found that TopIn (7-phenyl-6H-[1,2,5]oxadiazolo[3,4-e]indole 3-oxide) efficiently activated p53-mediated transcriptional activity and induced phosphorylation of p53 at Ser15, thereby stabilizing the p53 protein. Furthermore, TopIn upregulated the expression of p21(WAF1/CIP1), a downstream target of p53, and suppressed cellular proliferation in various colon cancer cells. Additionally, TopIn induced DNA fragmentation, caspase-3/7 activation and poly ADP ribose polymerase cleavage, typical biochemical markers of apoptosis, in p53 wild-type and mutated colon cancer cells. Finally, we found that TopIn inhibited topoisomerase I activity, but not topoisomerase II, in vitro and induced the formation of the topoisomerase I-DNA complex in HCT116 colon cancer cells. Unlike camptothecin (CPT) and its derivative SN38, TopIn did not affect the activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP) or multidrug-resistant protein-1 (MDR-1). These results suggest that TopIn may present a promising new topoisomerase I-targeting anti-tumor therapeutics.(C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 36 条
[1]
Ataka Masayuki, 2007, Yonago Acta Medica, V50, P81
[2]
Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain [J].
Bakos, E ;
Evers, R ;
Szakács, G ;
Tusnády, GE ;
Welker, E ;
Szabó, K ;
de Haas, M ;
van Deemter, L ;
Borst, P ;
Váradi, A ;
Sarkadi, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (48) :32167-32175
[3]
P53: An ubiquitous target of anticancer drugs [J].
Blagosklonny, MV .
INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :161-166
[4]
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer [J].
Bodurka, DC ;
Levenback, C ;
Wolf, JK ;
Gano, J ;
Wharton, JT ;
Kavanagh, JJ ;
Gershenson, DM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :291-297
[5]
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial [J].
Braun, Michael S. ;
Richman, Susan D. ;
Quirke, Philip ;
Daly, Catherine ;
Adlard, Julian W. ;
Elliott, Faye ;
Barrett, Jennifer H. ;
Selby, Peter ;
Meade, Angela M. ;
Stephens, Richard J. ;
Parmar, Mahesh K. B. ;
Seymour, Matthew T. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2690-2698
[6]
p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells [J].
Chen, XB ;
Ko, LJ ;
Jayaraman, L ;
Prives, C .
GENES & DEVELOPMENT, 1996, 10 (19) :2438-2451
[7]
Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human [J].
Choi, M. -K. ;
Kim, H. ;
Han, Y. -H. ;
Song, I. -S. ;
Shim, C. -K. .
XENOBIOTICA, 2009, 39 (02) :171-181
[8]
CONTI JA, 1996, J CLIN ONCOL, V14
[9]
CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO
[10]
2-G